IL277605B2 - בועיות המכילות מעכב pten ושימושיהם - Google Patents

בועיות המכילות מעכב pten ושימושיהם

Info

Publication number
IL277605B2
IL277605B2 IL277605A IL27760520A IL277605B2 IL 277605 B2 IL277605 B2 IL 277605B2 IL 277605 A IL277605 A IL 277605A IL 27760520 A IL27760520 A IL 27760520A IL 277605 B2 IL277605 B2 IL 277605B2
Authority
IL
Israel
Prior art keywords
pten
sirna
cells
exosomes
inhibitor
Prior art date
Application number
IL277605A
Other languages
English (en)
Other versions
IL277605A (he
IL277605B1 (he
Inventor
Offen Daniel
Levenberg Shulamit
Perets Nisim
Guo Shaowei
Original Assignee
Technion Res & Dev Foundation
Univ Ramot
Offen Daniel
Levenberg Shulamit
Perets Nisim
Guo Shaowei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation, Univ Ramot, Offen Daniel, Levenberg Shulamit, Perets Nisim, Guo Shaowei filed Critical Technion Res & Dev Foundation
Publication of IL277605A publication Critical patent/IL277605A/he
Publication of IL277605B1 publication Critical patent/IL277605B1/he
Publication of IL277605B2 publication Critical patent/IL277605B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL277605A 2018-03-29 2019-03-27 בועיות המכילות מעכב pten ושימושיהם IL277605B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649648P 2018-03-29 2018-03-29
PCT/IL2019/050355 WO2019186558A1 (en) 2018-03-29 2019-03-27 Vesicles comprising a pten inhibitor and uses of same

Publications (3)

Publication Number Publication Date
IL277605A IL277605A (he) 2020-11-30
IL277605B1 IL277605B1 (he) 2024-09-01
IL277605B2 true IL277605B2 (he) 2025-01-01

Family

ID=68058075

Family Applications (2)

Application Number Title Priority Date Filing Date
IL277605A IL277605B2 (he) 2018-03-29 2019-03-27 בועיות המכילות מעכב pten ושימושיהם
IL314908A IL314908A (he) 2018-03-29 2019-03-27 בועיות המכילות מעכב pten ושימושיהם

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL314908A IL314908A (he) 2018-03-29 2019-03-27 בועיות המכילות מעכב pten ושימושיהם

Country Status (7)

Country Link
US (2) US11648260B2 (he)
EP (1) EP3773506A4 (he)
JP (1) JP7518498B2 (he)
KR (1) KR20210005031A (he)
CN (1) CN112236131A (he)
IL (2) IL277605B2 (he)
WO (1) WO2019186558A1 (he)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133000A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
CN112972702A (zh) * 2019-12-17 2021-06-18 南京大学 用于治疗耐药菌感染的外泌体制剂
CN111467372B (zh) * 2020-03-03 2022-09-30 中山大学附属第一医院 间充质干细胞外泌体在制备延缓脊髓小脑性共济失调3型病程进展的药物中的应用
EP4132479A1 (en) 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof
CN111748520B (zh) * 2020-06-30 2021-02-19 四川大学 牙囊干细胞外泌体、制法及应用、其组合物及制法
WO2022081557A1 (en) * 2020-10-13 2022-04-21 Mayo Foundation For Medical Education And Research Compositions and methods promoting growth of peripheral nervous tissue
CA3200928A1 (en) * 2020-12-04 2022-06-09 Moon Jong Noh Treatment of spinal cord injury with pten inhibitor
WO2022215078A1 (en) * 2021-04-07 2022-10-13 Ramot At Tel-Aviv University Ltd. Modified cannabinoids and uses thereof
CN115245521B (zh) * 2021-04-28 2024-07-26 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的滴鼻剂及其在治疗脑神经血管疾病中的应用
CN113303280B (zh) * 2021-05-26 2022-11-01 中国人民解放军陆军特色医学中心 建立小鼠腹透腹膜损伤模型的方法及BMSCs外泌体的应用
CN114410632B (zh) * 2022-01-28 2024-08-30 江苏大学 特异性抑制PTEN基因的shRNA及应用
WO2023178500A1 (en) * 2022-03-22 2023-09-28 Beijing Theraxyte Bioscience Co. Ltd. Therapeutic vesicles and methods of processing the same
CN119183475A (zh) 2022-05-15 2024-12-24 诺艾克叟恩生物制药有限公司 抗pten rna干扰寡核苷酸及其用途
EP4551700A1 (en) 2022-07-10 2025-05-14 Nurexone Biologic Ltd. Rna interference oligonucleotides for inhibiting perineuronal network formation
CN116832218A (zh) * 2023-06-15 2023-10-03 山东第一医科大学第一附属医院(山东省千佛山医院) 用于脊髓损伤修复的个体化3D打印负载外泌体-siRNA的水凝胶支架系统及其应用
CN116712555B (zh) * 2023-07-14 2025-09-12 华中科技大学 一种靶向干预肿瘤神经微环境的载药细菌外膜囊泡及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074472A1 (en) * 2009-10-16 2016-03-17 The University Of British Columbia Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods
WO2017176894A1 (en) * 2016-04-06 2017-10-12 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
JP2009513487A (ja) 2003-06-27 2009-04-02 サイレンス・セラピューティクス・アーゲー 細胞溶解を誘発するための二本鎖リボ核酸の使用
US20070297985A1 (en) 2006-04-11 2007-12-27 Williams Bart O Method and composition for enhancing bone formation
EP2129397B1 (en) 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
PL2254586T3 (pl) 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
US20110189308A1 (en) 2008-03-17 2011-08-04 Asa Abeliovich Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
KR101840618B1 (ko) 2008-12-04 2018-03-20 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
SMT201700159T1 (it) 2009-02-17 2017-05-08 Univ Columbia Identificazione di forme extracellulari di pten che possono essere usate per trattare tumori
WO2011046983A2 (en) 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011088058A1 (en) * 2010-01-12 2011-07-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expressions of factor vii and pten genes
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
US10227593B2 (en) 2011-12-13 2019-03-12 Henry Ford Health System Methods, systems, and compositions for cell-derived/vesicle-based microRNA delivery
JP6450673B2 (ja) * 2012-04-03 2019-01-09 リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ 幹細胞微粒子
WO2013186735A2 (en) 2012-06-14 2013-12-19 Bar-Ilan Research And Development Company Ltd. Photothermal detection
KR102183406B1 (ko) 2013-03-15 2020-12-11 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 진단 및 치료를 위한 엑소좀 내 miRNA 생합성
SG11201603506PA (en) 2013-11-04 2016-05-30 Tissuegene Inc Treatment of damaged nerve with pten inhibitor
WO2015105957A1 (en) 2014-01-08 2015-07-16 Shriners Hospitals For Children Pten antagonist peptides and methods of using the same
US10513710B2 (en) 2014-04-18 2019-12-24 University Of Massachusetts Exosomal loading using hydrophobically modified oligonucleotides
KR101834841B1 (ko) * 2015-06-01 2018-03-06 아주대학교 산학협력단 줄기세포의 고활성 유도 방법
EA201890006A1 (ru) * 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
EP3430024A4 (en) 2016-03-15 2019-11-13 Codiak BioSciences, Inc. THERAPEUTIC MEMBRANE VESICLES
WO2017173034A1 (en) 2016-03-30 2017-10-05 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
AU2017265937A1 (en) 2016-05-16 2018-11-22 Exostem Biotec Ltd. Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
GB2552460A (en) 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
WO2018022927A1 (en) * 2016-07-27 2018-02-01 BioAxone BioSciences, Inc. TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS
CN109843305B (zh) * 2016-08-14 2023-03-10 雷蒙特亚特特拉维夫大学有限公司 治疗神经障碍的间充质细胞来源的外泌体
CN110402146A (zh) 2016-11-03 2019-11-01 埃克森蒂姆生物技术公司 间充质干细胞群、其产物及其用途
CN111093681B (zh) 2017-07-16 2024-07-16 雷蒙特亚特特拉维夫大学有限公司 人类口腔粘膜干细胞分泌蛋白质组

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074472A1 (en) * 2009-10-16 2016-03-17 The University Of British Columbia Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods
WO2017176894A1 (en) * 2016-04-06 2017-10-12 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE, HYUN JOON, ET AL., DELAYED APPLICATIONS OF L1 AND CHONDROITINASE ABC PROMOTE RECOVERY AFTER SPINAL CORD INJURY., 31 December 2012 (2012-12-31) *
LI, HUA, ET AL., SILENCING OF PMEPA1 ACCELERATES THE GROWTH OF PROSTATE CANCER CELLS THROUGH AR, NEDD4 AND PTEN., 31 December 2015 (2015-12-31) *
NIU, YANAN, ET AL., PTEN ACTIVATION BY DNA DAMAGE INDUCES PROTECTIVE AUTOPHAGY IN RESPONSE TO CUCURBITACIN B IN HEPATOCELLULAR CARCINOMA CELLS., 31 December 2016 (2016-12-31) *

Also Published As

Publication number Publication date
JP2021519283A (ja) 2021-08-10
US11648260B2 (en) 2023-05-16
IL314908A (he) 2024-10-01
RU2020132733A (ru) 2022-04-29
EP3773506A4 (en) 2021-12-22
JP7518498B2 (ja) 2024-07-18
IL277605A (he) 2020-11-30
US20210077520A1 (en) 2021-03-18
EP3773506A1 (en) 2021-02-17
KR20210005031A (ko) 2021-01-13
US20230330130A1 (en) 2023-10-19
WO2019186558A1 (en) 2019-10-03
CN112236131A (zh) 2021-01-15
IL277605B1 (he) 2024-09-01

Similar Documents

Publication Publication Date Title
US20230330130A1 (en) Vesicles comprising a pten inhibitor and uses of same
JP7504482B2 (ja) ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
CN113811311A (zh) 用于组织特异性apoe调节的寡核苷酸
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
EP3132044A1 (en) Exosomal loading using hydrophobically modified oligonucleotides
EP2319519B1 (en) Composition for inhibiting expression of target gene
JP5888572B2 (ja) 神経保護の提供におけるマイクロｒｎａ１９５の使用法
JP2018531046A6 (ja) 核酸ベースのｔｉａ−１阻害剤
JP2018531046A (ja) 核酸ベースのｔｉａ−１阻害剤
RU2800729C2 (ru) Везикулы, содержащие ингибитор pten, и их применение
US20250136992A1 (en) Anti-pten rna interference oligonucleotides and uses thereof
HK40044377A (en) Vesicles comprising a pten inhibitor and uses of same
US20250388899A1 (en) Rna interference oligonucleotides for inhibiting perineuronal network formation
US20100292454A1 (en) Neuronal regeneration promoting agent
EP4551700A1 (en) Rna interference oligonucleotides for inhibiting perineuronal network formation
WO2025182103A1 (ja) 脳梗塞の機能予後改善用組成物